StopDown
News · 29 August 2026BiodimensionHuman-relevant tissue models for testing

Biodimension builds human tissue alternatives to animal testing

By · Editor ·

BengaluruFounded 2021
  • Biodimension makes reconstructed human tissues and organoids for drug discovery and cosmetics testing
  • The Bengaluru startup uses human cells on biomaterial scaffolds to create skin models and miniature organs
  • Its technology aims to replace animal testing, which fails to predict human responses accurately

What happened

  • Biodimension was founded in 2021 in Bengaluru.
  • The startup builds human-relevant alternatives to animal testing.
  • It uses reconstructed human tissues and organoids (miniature versions of organs made from patient cells).
  • Its technology is applied in drug discovery, pharmaceutical research, cosmetics, and personal care.
  • The company has a 6,000-square-foot NAMs facility (new approach methodologies) in Bengaluru.
  • Biodimension is working towards OECD Test Guidelines but currently limits its scope to research use.

Why it matters

  • About 90% of drugs entering human trials fail because animal models don't predict human response accurately.
  • The current testing system cannot represent human biology adequately.
  • Biodimension started with skin models due to regulatory pressure in cosmetics and personal care to end animal testing.

The business

  • Biodimension creates reconstructed human tissues using human cells on biomaterial scaffolds like collagen and gelatin.
  • Its skin models are grown with an air-exposed top surface to mimic the skin's barrier function.
  • Organoids self-organise from patient cells into miniature versions of tumours or organs.
  • Validation involves three levels: structural (correct layers and proteins), functional (reference chemicals), and statistical (repeated batches with reported variation).
  • The technology serves drug discovery, pharmaceutical research, cosmetics, and personal care industries.

The founders

Manokumar

Founder
  • Studied biotechnology at VIT (Vellore Institute of Technology).
  • Has industry experience before founding Biodimension.

Ranjith Kumar Velusamy

Co-founder
  • Studied biotechnology at VIT.

Pradeep Arunachalam

Co-founder
  • Studied biotechnology at VIT.

In numbers

6,000 square feetFacility size · 2026

What happens next

  • Biodimension is working towards OECD Test Guidelines for regulatory acceptance.
  • Currently its products are for research use only.

Words to know

Organoid
A miniature, simplified version of an organ grown from stem cells that mimics the structure and function of the real organ.
OECD Test Guidelines
Internationally accepted standard methods set by the Organisation for Economic Co-operation and Development for testing chemicals and products.
NAMs
New Approach Methodologies — non-animal testing methods that use human cells or tissues.
Biomaterial scaffold
A natural or synthetic material structure that supports the growth of cells into a tissue.

The numbers around it

Biodimension has 1 funding rounds in StopDown's archive, ₹8 crore raised in all.

#The numbers around it
WhenRoundAmountLed by
11 June 2026Round₹8 CrIAN Angel Fund

Healthcare & Life Sciences in August 2026: 10 rounds with a disclosed amount, $139 million in all; the biggest was Biodeal Pharmaceuticals (₹385 crore). Every sector this year →

Read it as a card in the app

Terms in this story

  • Startup: A startup is a young company built to find a new way of doing something and to grow fast, usually by serving many customers at little extra cost. India also has a legal definition for scheme benefits: under ten years old, turnover under ₹200 crore, and working on innovation or a scalable model.

Everything on Biodimension → · All startup news on 29 August 2026 →

Is this Biodimension? Get your “Featured on StopDown” badge →